🎉 M&A multiples are live!
Check it out!

Molecure Valuation Multiples

Discover revenue and EBITDA valuation multiples for Molecure and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Molecure Overview

About Molecure

Molecure SA is a biopharmaceutical company engaged in discovering, developing, and commercializing novel therapeutics for neoplastic and inflammatory diseases. The company is focused on discovering and developing molecules with potential to become first-in-class or best-in-class drugs worldwide to treat unmet medical needs.


Founded

2012

HQ

Poland
Employees

88

Website

molecure.com

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$37.7M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Molecure Financials

Molecure has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Molecure achieved revenue of n/a and an EBITDA of -$7.1M.

Molecure expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Molecure valuation multiples based on analyst estimates

Molecure P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $0K n/a XXX XXX XXX
Gross Profit -$0.4M -$0.4M XXX XXX XXX
Gross Margin -1634566% -Infinity% XXX XXX XXX
EBITDA -$4.2M -$7.1M XXX XXX XXX
EBITDA Margin -16413896% -Infinity% XXX XXX XXX
Net Profit -$3.9M -$4.7M XXX XXX XXX
Net Margin -15263697% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Molecure Stock Performance

As of April 15, 2025, Molecure's stock price is PLN 8 (or $2).

Molecure has current market cap of PLN 158M (or $40.5M), and EV of PLN 147M (or $37.7M).

See Molecure trading valuation data

Molecure Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$37.7M $40.5M XXX XXX XXX XXX n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Molecure Valuation Multiples

As of April 15, 2025, Molecure has market cap of $40.5M and EV of $37.7M.

Molecure's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Molecure's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Molecure and 10K+ public comps

Molecure Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $37.7M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA -5.3x XXX XXX XXX
P/E -5.0x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -1.8x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Molecure Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Molecure Valuation Multiples

Molecure's NTM/LTM revenue growth is n/a

Molecure's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $0.1M for the same period.

Over next 12 months, Molecure's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Molecure's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Molecure and other 10K+ public comps

Molecure Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -100% XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth 67% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $0.1M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Molecure Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Molecure M&A and Investment Activity

Molecure acquired  XXX companies to date.

Last acquisition by Molecure was  XXXXXXXX, XXXXX XXXXX XXXXXX . Molecure acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Molecure

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Molecure

When was Molecure founded? Molecure was founded in 2012.
Where is Molecure headquartered? Molecure is headquartered in Poland.
How many employees does Molecure have? As of today, Molecure has 88 employees.
Is Molecure publicy listed? Yes, Molecure is a public company listed on WAR.
What is the stock symbol of Molecure? Molecure trades under MOC ticker.
When did Molecure go public? Molecure went public in 2018.
Who are competitors of Molecure? Similar companies to Molecure include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Molecure? Molecure's current market cap is $40.5M
Is Molecure profitable? Yes, Molecure is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.